

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
A collection of information which contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sh

1

of 1

Complete if Known

Application Number	10/627,499
Filing Date	07/25/2003
First Named Inventor	Kink et al.
Art Unit	1646
Examiner Name	Xie
Attorney Docket Number	OPHDO-8311

Examiner Signature		Date Considered	4/13/07
-----------------------	---	--------------------	---------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ²Applicant's unique citation designation number (optional). ³See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ⁴Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁷Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

FORM PTO-1449 Commerce (Modified)				U.S. Department of Patent and Trademark Office		Attorney Docket No.: OPHD-08311		Serial No.: 10/627,499	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(Use Several Sheets If Necessary)</small> <small>(37 CFR § 1.98(b))</small>						Applicant: John A. Kink et al.			
						Filing Date: 7/25/2003		Group Art Unit: 1646	
U.S. PATENT DOCUMENTS									
Examiner Initials		Serial / Patent Number	Issue Date	Applicant / Patentee		Class	Subclass	Filing Date	
X2	1	4,477,432	10/16/84	Hardie		424	85	4/05/82	
	2	5,604,231	2/18/97	Smith et al.		514	256	1/06/95	
	3	5,614,540	3/25/97	Christensen		514	362	5/18/95	
	4	5,654,407	8/05/97	Boyle et al.		530	388.15	5/05/95	
	5	5,436,154	7/25/95	Barbanti et al.		435	240.27	12/13/91	
	6	5,385,901	1/31/95	Kaplan et al.		514	231.5	10/02/92	
	7	4,870,163	9/26/89	Rubin et al.		530	43	8/29/85	
	8	5,656,272	8/12/97	Le et al.		424	133.1	2/04/94	
	9	4,676,982	6/30/87	Hassig		424	85	08/04/86	
	10	4,677,064	6/30/87	Mark et al.		435	68	5/02/85	
	11	4,748,018	5/31/88	Strole et al.		424	87	6/19/84	
	12	5,080,895	1/14/92	Tokoro		424	85.8	4/01/91	
	13	5,487,984	1/30/96	Allet et al.		435	69.5	12/20/85	
	14	5,672,347	9/30/97	Aggarwal et al.		424	139.1	5/05/95	
	15	5,707,622	1/13/98	Fong et al.		424	145.1	3/01/95	
	16	5,753,228	5/19/98	Sterling et al.		424	151.1	12/05/94	
	17	5,772,999	6/30/98	Greenblatt et al.		424	187.1	7/30/96	
	18	5,795,967	8/18/98	Aggarwal et al.		530	388.23	6/07/95	
↓	19	5,420,253	5/30/95	Emery et al.		530	423	9/09/93	
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS									
		Document Number	Publication Date	Country / Patent Office		Class	Subclass	Translation	
X2	20	WO98/14209	04/09/98	PCT				Yes	No
	21	WO96/33204	10/24/96	WIPO					
↓	22	WO97/15327	05/01/97	PCT					
↓	23	EP 0 155 549 B1	03/20/91	EPO					
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)									
X2	24	Polson et al., "Antibodies to Proteins from Yolk of Immunized Hens," <i>Immunol. Comm.</i> , 9:495-514 (1980)							
	25	Okayasu et al., "A Novel Method in the Induction of Reliable Experimental Acute and Chronic Ulcerative Colitis in Mice," <i>Gastroenterology</i> , 98:694-702 (1990)							
	26	Kojouharoff et al., "Neutralization of tumour necrosis facto (TNF) but not of IL-1 reduces inflammation in chronic dextran sulphate sodium-induced colitis in mice," <i>Clin. Exp. Immunology</i> , 107: 353-358 (1997)							
	27	Olson et al., "Antiserum to Tumor Necrosis Factor and failure to Prevent Murine Colitis," <i>J. Pediatric Gastroenterology and Nutrition</i> 21: 410-418 (1995)							
↓	28	Stack et al., "The Effects of CDP571, An Engineered Human IgG α 4 Anti-TNF α Antibody in Crohn's Disease", <i>Gastroenterology</i> , 110:A1018 (1996)							
Examiner:	<i>Kink</i>				Date Considered:	4/13/07			
EXAMINER:	Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

FORM PTO-1449 Commerce (Modified)		U.S. Department of Patent and Trademark Office	Attorney Docket No.: OPHD-08311	Serial No.: 10/627,499
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary) (37 CFR § 1.98(b))			Applicant: John A. Kink <i>et al.</i>	
			Filing Date: 7/25/2003	Group Art Unit: 1646

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)


X 2	29	Rutgeerts <i>et al.</i> , "Retreatment with Anti-TNF- α Chimeric Antibody (cA2) Effectively maintains cA3-Induced remission in Crohn's Disease," <i>Gastroenterology</i> 112:A1078 (1997)
	30	Van Dullemon <i>et al.</i> , "Treatment of Crohn's Disease with Anti-Tumor Necrosis Factor Chimeric Monoclonal Antibody (cA2)," <i>Gastroenterology</i> 109:129-138 (1995)
	31	Targan <i>et al.</i> , "A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease," <i>New England Journal of Medicine</i> , 337:1029-1035 (1997)
	32	Plevy <i>et al.</i> , "A Role for TNF- α and Mucosal T Helper-1 Cytokines in the Pathogenesis of Crohn's Disease," <i>Journal of Immunology</i> , 6277-6282 (1997)
	33	Sartor, "Current Concepts of the Etiology and Pathogenesis of Ulcerative Colitis and Crohn's Disease," <i>Inflammatory Bowel Disease</i> , 24:475-507 (1995)
	34	Sartor, "Pathogenesis and Immune Mechanisms of Chronic Inflammatory Bowel Diseases," <i>Gastroenterology</i> , 92:SS-11S (1997)
	35	Robinson, "Optimizing Therapy for Inflammatory Bowel Disease," <i>American Journal of Gastroenterology</i> , 92:12-17 (1997)
	36	Targan and Shanahan, "Pseudomembranous Colitis and Clostridium difficile Infection," <i>Inflammatory Bowel Disease From Bench to Bench</i> , 51:743-755 (1994)
	37	Ogorek and Fisher, "Differentiation Between Crohn's Disease and Ulcerative Colitis," in <i>Inflammatory Bowel Disease</i> , Katz, ed., 78:1249-1257 (1994)
	38	Cameron, "Anti-TNF- α treatments set to mop up in rheumatoid arthritis," <i>Research and Development</i> , pp.9-10 (1998)
	39	Elliott <i>et al.</i> , "Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis," <i>Lancet</i> , 344:1105-1110 (1994)
	40	Elliott <i>et al.</i> , "Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis," <i>Lancet</i> 344:1125-1127 (1994)
	41	Gibson, "Inflammatory Bowel Disease Current Concepts in Pathogenesis and Therapy," <i>Clin. Immunother.</i> , 2(2):135-160 (1994)
	42	Bell and Wallace, "Inflammatory Bowel Disorders Current and Future Drugs that Modulate Adhesion Molecules," <i>BioDrugs</i> , 7(4):273-284 (1997)
	43	Opal <i>et al.</i> , "Potential Hazards of Combination Immunotherapy in the Treatment of Experimental Septic Shock," <i>J. Infect. Dis.</i> , 173:1415-1421 (1996)
	44	Russell <i>et al.</i> , "Combined Inhibition of Interleukin-1 and Tumor Necrosis Factor in Rodent Endotoxemia: Improved Survival and Organ Function," <i>J. Infect. Dis.</i> , 171:1528-1538 (1995)
	45	Levine <i>et al.</i> , "Intravenous Immunoglobulin Therapy for Active, Extensive and Medically Refractory Idiopathic Ulcerative or Crohn's Colitis" <i>Am J Gastroenterol</i> , 87:91-100 (1992)
	46	Neurath <i>et al.</i> , "Predominant Pathogenic role of Tumor Necrosis Factor in Experimental Colitis in Mice," <i>Eur J Immunol</i> 27:1743-1750 (1997)
	47	Neurath <i>et al.</i> , "Antibodies to Interleukin 12 Abrogate Established Experimental Colitis in mice," <i>J Exp Med</i> 182:1281-1290 (1995)
	48	Feldmann <i>et al.</i> , "Cytokine Expression and Networks in Rheumatoid Arthritis: Rationale for Anti-TNFalpha Antibody Therapy and its Mechanism of Action," <i>J Inflammation</i> 47:90-96 (1996)
	49	Reimund <i>et al.</i> , "Increased production of tumor necrosis factor-alpha, interleukin-1-beta and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease" <i>Gut</i> 39:684-689 (1996)
	50	Duchmann <i>et al.</i> , "Tolerance towards resistant intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12," <i>Eur J Immunol</i> 26:934-938 (1996)
	51	Tsubokura <i>et al.</i> , "Oral administration of antibodies as prophylaxis and therapy in <i>Campylobacter jejuni</i> -infected chickens," <i>Clin Exp Immunol</i> 108:451-455 (1997)
	52	Nicholls <i>et al.</i> , "Cytokines in stools of children with inflammatory bowel disease or infective diarrhoea," <i>J Clin Path</i> 46:757-760 (1993)
	53	Tjellström <i>et al.</i> , "Oral immunoglobulin treatment in Crohn's disease," <i>Acta Paediatr</i> 86:221-223 (1997)
	54	Rubalteli <i>et al.</i> , "Prevention of necrotizing enterocolitis in neonates at risk by oral administration of monomeric IgG," <i>Dev Pharmacol Ther</i> 17:138-143 (1991)

Examiner:

Date Considered:

4/13/07

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 Commerce (Modified)		U.S. Department of Patent and Trademark Office	Attorney Docket No.: OPHD-08311	Serial No.: 10/627,499
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary) (37 CFR § 1.98(b))			Applicant: John A. Kink <i>et al.</i>	
			Filing Date: 7/25/2003	Group Art Unit: 1646
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)				
X 2	55	Armstrong <i>et al.</i> , "Tumor necrosis factor and inflammatory bowel disease," <i>British Journal of Surgery</i> 84:1051-1058 (1997)		
	56	Monteleone <i>et al.</i> , "Interleukin 12 (IL-12) is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells (LPMCs)," <i>Gastroenterology</i> 112:1169-1178 (1997)		
	57	Starnes <i>et al.</i> , "Anti-IL-6 monoclonal antibodies protect against lethal <i>Escherichia coli</i> infection and lethal tumor necrosis factor-alpha challenge in mice" <i>J Immuno</i> 12:4185-4191 (1990)		
	58	Doherty <i>et al.</i> , "Evidence for IFN-gamma as a mediator of the lethality of endotoxin and tumor necrosis factor-alpha" <i>J Immuno</i> 5:1666-1670 (1992)		
	59	Manthey <i>et al.</i> , "The role of cytokines in host responses to endotoxin" <i>Reviews in Med Microbio</i> 3:72-79 (1992)		
	60	Dalekos, <i>et al.</i> , "High concentrations of soluable interleukin-2 receptors and interleukin-6 in active ulcerative cells" <i>Hellenic J Gastro</i> 8:319-327 (1995)		
	61	Evans, <i>et al.</i> , "Treatment of ulcerative colitis with an engineered human anti-TNF-alpha antibody CDP571" <i>Aliment Pharmacol Ther</i> 11:1031-1035 (1997)		
	62	Hoang, <i>et al.</i> , "Symposium: Role of cytokines in inflammatory bowel disease" <i>Acte Gastro-Enterologica Belgica</i> 57:219-223 (1994)		
	63	van Hogenzand, <i>et al.</i> , "Selective immunomodulation in patients with inflammatory bowel disease-future therapy or reality?" <i>Netherlands J of Med</i> 48:64-67 (1996)		
	64	Zacharchuk <i>et al.</i> , "Macrophage-mediated cytotoxicity: Role of a soluble macrophage cytotoxic factor similar to lymphotoxin and tumor necrosis factor," <i>PNAS USA</i> 80:6341-6345 (1983)		
	65	Zacharchuk, Charles Michael, "A Macrophage Cytotoxic Factor: Immunochemical and Functional Characterization," Dissertation Abstract (1983)		
	66	Pennica <i>et al.</i> , "Human tumor necrosis factor: precursor structure, expression and homology to lymphotoxin," <i>Nature</i> 312:724-729 (1984)		
	67	Ruff, Michael Roland, "Mechanism of Action of a Serum Oncolytic Protein, Rabbit Tumor Necrosis Factor," Dissertation Abstract. (1980)		
	68	Beck <i>et al.</i> , "Cytokines in inflammatory bowel disease," <i>Mediators of Inflammation</i> 6:95-103 (1997)		
	69			
	70			
	71			
	72			
	73			
	74			
	75			
	76			
	77			
	78			
	79			
Examiner:			Date Considered:	4/13/07
EXAMINER:	Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			